• Is decentralization of clinical trials still relevant in 2025?
• Incorporating remote monitoring tools such as wearables into clinical trials
• An overview of new tools and solutions available on the market
• The growth of GenAI: when will this become widely used in clinical research?
• Balancing new techno
MODERATOR:
Rich Polgar, Managing Director, Danforth Advisors
PANELLISTS:
Ashlyn Jose, Director, Clinical Operations, Kyowa Kirin, Inc
Ram Raju, Senior Vice President and Community Health Investment Officer, Northwell Health
Kristen Olszyk, Vice President, Clinical Operations, Neuraptive Therapeutics
Stefanie Kuhner, Head of Clinical Technology, Innovation and Patient Recruitment, Bristol Myers
Squibb
As the clinical research industry pushes toward innovative solutions to increase inclusivity and access, it’s time to look beyond traditional site-based trial models and digital platforms. Expanding access isn’t just about technology-centered solutions – it’s about rethinking where and how trials happen. This session explores how community-based research models, including mobile research sites, mobile clinicians, and flexible visit options, are redefining what it means to bring research to patients. This session will explore how building trust and presence in local communities leads to better enrollment, stronger retention, and more representation data.
• Working closely with FSP vendors: how much oversight do you need?
• Benefits and challenges of moving to an FSP outsourcing model
• Comparing vendor management strategies between pharma and biotechs: do you need a different
approach?
• Why is FSP becoming a popular outsourcing model: what benefits can this offer sponsors?
MODERATOR:
Rich Polgar, Managing Director, Danforth Advisors
PANELLISTS:
Melanie Goodwin, Director, Clinical Outsourcing,
Immunocore
Russell Bland, Director, Clinical Outsourcing and
Innovation, Jazz Pharmaceuticals
Terry Katz, Senior Director, Biostatistics and Data
Management Planning and Functional Excellence, Daiichi
Sankyo, Inc
Clinical R&D outsourcing needs and models have evolved over the last few years. Many biopharma companies are transitioning to a function-driven sourcing model where we can have a set of fit-for-purpose preferred suppliers to bring in flexibility and agility. Challenges in sourcing needs, pros and cons of different sourcing models will be discussed.
